ClinicalTrials.gg
RecruitingNCT07245017Updated Dec 1, 2025

JN002 for the Treatment of Dry Eye Disease

An Early Phase 1 interventional study of Placebo Ophthalmic Solution (Vehicle) and JN002 Ophthalmic Solution (0.05 mg/mL) in Dry Eye, sponsored by Eye & ENT Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Eye & ENT Hospital of Fudan University · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Dry Eye Syndromes with a site in China — 28 open to participants now, 30 under way, 3 of them phase 3. Dry Eye Syndromes · China.

Planned enrollment
67th of 83
30 · median 80
Started
2025
with 5 others
Phase 1
7 of 106
3 open now
Primary completion
2026-03
later than 12 of 29 live
Registered
93rd of 106
by date
Lead sponsor
3 of 106
Eye & ENT Hospital of Fudan University

Among the 106 studies in Dry Eye Syndromes with a site in China, this one is the 67th largest by planned enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2025, is one of 7 in phase 1, reaches primary completion later than 12 of the 29 other live ones, and was the 93rd registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

28 of the 106 studies in Dry Eye Syndromes with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Dry Eye Syndromes with a site in China, or all of them as a file.
02

Study summary

This is a first-in-human, single-center, randomized, double-blind, placebo-controlled clinical trial designed to:·Evaluate the efficacy of JN002 Ophthalmic Solution in treating dry eye disease (DED)·Assess the safety of JN002 Ophthalmic SolutionResearchers will compare three groups-placebo (vehicle), low-dose JN002 (0.05 mg/mL), and high-dose JN002 (0.1 mg/mL)-to evaluate whether JN002 Ophthalmic Solution improves DED outcomes and to assess its safety profile relative to placebo.Participants will:·Complete a baseline assessment (V0) including ocular exams, OSDI questionnaire, and systemic evaluation;·Administer the assigned study medication three times daily (1 drop per eye per administration);·Attend three follow-up visits (V1: 7±2 days, V2: 14±2 days, V3: 28±2 days post-treatment initiation) for ocular assessments, symptom queries, and adherence checks;·Undergo a full repeat of baseline assessments at V3 to evaluate treatment effects and safety profile

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years or older
  2. Ocular Surface Disease Index (OSDI) score ≥ 13
  3. Schirmer I test result ≤ 10 mm/5 min
  4. Fluorescein tear film break-up time \< 10 seconds
  5. Corneal Fluorescein Staining score (National Eye Institute grading) ≥ 4
  6. Best corrected visual acuity ≥ 0.6
  7. Intraocular pressure ≤ 21 mmHg
  8. Voluntarily agrees to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. History of refractive surgery or intraocular surgery within the past 6 months
  2. ocular abnormalities at screening or baseline, including but not restricted to eye trauma, pterygium, allergic keratoconjunctivitis, active ocular infections, or abnormal ocular structures
  3. Uncontrolled ocular or systemic diseases
  4. Other conditions deemed by the investigators likely to interfere with study parameters
  5. Females with plans for pregnancy at enrollment or during the treatment period
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Group

    Placebo ophthalmic solution

    Drug: Placebo Ophthalmic Solution (Vehicle)

  • Experimental
    Low-Dose JN002 Group

    JN002 Ophthalmic Solution at a concentration of 0.05 mg/mL

    Drug: JN002 Ophthalmic Solution (0.05 mg/mL)

  • Experimental
    High-Dose JN002 Group

    JN002 Ophthalmic Solution at a concentration of 0.1 mg/mL

    Drug: JN002 Ophthalmic Solution (0.1 mg/mL)

Interventions

  • DrugPlacebo Ophthalmic Solution (Vehicle)

    Placebo ophthalmic solution (vehicle without active ingredient JN002), administered three times daily (1 drop per eye per dose) for 28 ± 2 consecutive days

  • DrugJN002 Ophthalmic Solution (0.05 mg/mL)

    JN002 Ophthalmic Solution at a concentration of 0.05 mg/mL, administered three times daily (1 drop per eye per dose) for 28 ± 2 consecutive days

  • DrugJN002 Ophthalmic Solution (0.1 mg/mL)

    JN002 Ophthalmic Solution at a concentration of 0.1 mg/mL, administered three times daily (1 drop per eye per dose) for 28 ± 2 consecutive days

06

What researchers measure

Primary outcomes

  1. Corneal Fluorescein Staining score

    Change from baseline in Corneal Fluorescein Staining (CFS) score at the 7±2 days, 14±2 days and 28±2 days follow-up. CFS is evaluated following the guidelines from the National Eye Institute: the corneal surface is divided into five regions (central, superior, inferior, nasal, temporal), with each region assigned a score ranging from 0 to 3, resulting in a total possible score of 0 to 15-higher scores indicate more severe corneal epithelial damage and a worse clinical outcome.

    Time frame: Baseline, 7±2 days, 14±2 days and 28 ± 2 days

  2. Ocular Surface Disease Index score

    Change from baseline in Ocular Surface Disease Index (OSDI) score at the 7±2 days, 14±2 days and 28±2 days follow-up. OSDI is assessed via a 12-item self-reported questionnaire, where raw scores are converted to a standardized 0-100 scale through a specific calculation, with higher scores indicating more severe ocular surface disease symptoms.

    Time frame: Baseline, 7±2 days, 14±2 days and 28±2 days

Secondary outcomes

  1. Schirmer I test

    Change from baseline in Schirmer I test result (measuring aqueous tear secretion) at the 28±2 days follow-up.

    Time frame: Baseline and 28 ± 2 days

  2. Tear meniscus height

    Change from baseline in tear meniscus height at the 28±2 days follow-up.

    Time frame: Baseline and 28 ± 2 days

  3. Non-invasive tear film break-up time

    Change from baseline in non-invasive tear film break-up time (measured via Keratograph 5M) at the 28±2 days follow-up.

    Time frame: Baseline and 28 ± 2 days

  4. Tear inflammatory cytokines

    Change from baseline in tear inflammatory cytokines (IL-1β, IL-6, IL-17A, TNF-α, INF-γ) levels at the 28±2 days follow-up.

    Time frame: Baseline and 28 ± 2 days

Other outcomes

  1. Corneal dendritic cell density

    Change from baseline in corneal dendritic cell density at the 28±2 days follow-up, assessed and quantified via in vivo corneal confocal microscopy (IVCM)-a specialized imaging tool for ocular surface evaluation.

    Time frame: Baseline and 28 ± 2 days

  2. Best-corrected visual acuity

    Best-corrected visual acuity assessed at baseline, 7±2 days, 14±2 days, and 28±2 days.

    Time frame: Baseline, 7 ± 2 days, 14 ± 2 days, and 28 ± 2 days

  3. Intraocular pressure

    Intraocular pressure assessed at baseline, 7±2 days, 14±2 days, and 28±2 days.

    Time frame: Baseline, 7±2 days, 14±2 days, and 28±2 days.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Mar 2026, 4 months after the start.

Of 34 phase 1 interventional studies under Dry Eye Syndromes, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 24, 2025
StartActual
Nov 24, 2025
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07245017
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Nov 24, 2025
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Dec 1, 2025

Study contacts

Jiaxu Hong
Contact
Jiaxu.hong@fdeent.org
021-64377134

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion